Structural and Functional Characterization of the Human Perlecan Gene Promoter
TRANSCRIPTIONAL ACTIVATION BY TRANSFORMING GROWTH FACTOR-beta VIA A NUCLEAR FACTOR 1-BINDING ELEMENT*

(Received for publication, July 26, 1996, and in revised form, October 18, 1996)

Renato V. Iozzo Dagger §, Jhuma Pillarisetti Dagger , Bela Sharma Dagger , Alan D. Murdoch Dagger , Keith G. Danielson Dagger , Jouni Uitto §par ** and Alain Mauviel par

From the Dagger  Department of Pathology, Anatomy, and Cell Biology, the § Kimmel Cancer Center, the par  Department of Dermatology and Cutaneous Biology, and the ** Jefferson Institute of Molecular Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

Perlecan, a modular heparan sulfate proteoglycan of basement membranes and cell surfaces, plays a crucial role in regulating the assembly of extracellular matrices and the binding of nutrients and growth factors to target cells. To achieve a molecular understanding of perlecan gene regulation, we isolated the 5'-flanking region and investigated its functional promoter activity and its response to cytokines. Transient cell transfection assays, using plasmid constructs harboring the perlecan promoter linked to the chloramphenicol acetyltransferase reporter gene, demonstrated that the largest ~2.5-kilobase construct contained maximal promoter activity. This promoter region was functionally active in a variety of cells of diverse histogenetic origin, thus corroborating the widespread expression of this gene product. Stepwise 5' deletion analyses demonstrated that the -461-base pair (bp) proximal promoter retained ~90% of the total activity, and internal deletions confirmed that the most proximal sequence was essential for proper promoter activity. Nanomolar amounts of transforming growth factor-beta induced 2-3-fold perlecan mRNA and protein core levels in normal human skin fibroblasts, and this induction was transcriptionally regulated; in contrast, tumor necrosis factor-alpha had no effect and was incapable of counteracting the effects of TGF-beta . Using additional 5' deletions and DNase footprinting analyses, we mapped the TGF-beta responsive region to a sequence of 177 bp contained between -461 and -285. This region harbored a 14-bp element similar to a TGF-beta -responsive element present in the promoters of collagen alpha 1(I), alpha 2(I), elastin, and growth hormone. Electrophoretic mobility shift assays and mutational analyses demonstrated that the perlecan TGF-beta -responsive element bound specifically to TGF-beta -inducible nuclear proteins with high affinity for NF-1 member(s) of transcription factors.


INTRODUCTION

Perlecan (1), a modular proteoglycan carrying primarily heparan sulfate side chains, is present in virtually all vascularized tissues (2, 3). This proteoglycan is expressed either as an integral component of basement membranes or diffusely in connective tissues as diverse as ovarian stroma, skin, and cartilage (4, 5). Perlecan epitopes are distributed along the sinusoidal spaces of the liver, spleen, bone marrow, and lymphoreticular system including thymus, tonsils, and lymph nodes (4). The latter suggests that perlecan may be important for the normal development and function of the bone marrow and lymphoreticular system (6). Analysis of the primary structure of human perlecan reveals an assembly of five consecutive domains with homology to molecules involved in the control of cell proliferation, lipoprotein uptake, and adhesion (1, 7). This molecular architecture suggests that perlecan may play a variety of biological functions in different tissue locations (8). For example, perlecan can bind several growth factors via its heparan sulfate side chains (9, 10), while the protein core perlecan can bind nidogen (11) and various integrins (12, 13). Recently, we provided direct evidence that basic fibroblast growth factor binds to heparan sulfate chains attached to domain I and that the concerted action of heparanases and proteases could modulate the bioavailability of this growth factor in vivo (14). The perlecan-mediated induction of angiogenesis is supported by the observation that metastatic melanoma cells exhibit a marked induction of this gene, and this increase correlates with an abundant deposition of perlecan proteoglycan in the neovascularized tumor stroma (15). In addition, perlecan binds to fibronectin (16), gamma -interferon (17), and TGF-beta 1 (18), and recent evidence indicates that perlecan can be adhesive for fibroblasts, endothelial cells (19), and chondrocytes (5) while being anti-adhesive for hematopoietic cells (19). These opposing functions are not surprising given the multipurpose structure of the protein core and the complexity of its potential post-translational modifications. The latter may result in heparan sulfate side chains either alone (20) or in combination with chondroitin sulfate (21), fatty acylation (22), or the total lack of glycanation of the protein core which can be produced as a glycoprotein (5, 23).

Perlecan expression is up-regulated by nanomolar concentrations of TGF-beta in human colon carcinoma cells (24) and murine uterine epithelial cells (25). TGF-beta also stimulates the synthesis of basic fibroblast growth factor-binding heparan sulfate proteoglycans in mouse 3T3 cells (26). Moreover, it is quite evident that perlecan is a key regulator of the complex interactions that take place during neovascularization, and that the interplay amongst TGF-beta , basic fibroblast growth factor, and perlecan is biologically relevant (3, 14).

We previously reported the complete genomic organization of the human perlecan HSPG2 gene, including 0.77 kb of the 5'-flanking region (27). In the current investigation we cloned and sequenced 2.5 kb of the upstream region, and, by using transient cell transfection assays and stepwise 5' or internal deletions, we demonstrate functional promoter activity of the perlecan gene. The perlecan promoter was transcriptionally activated by TGF-beta but was unresponsive to TNF-alpha . A TGF-beta -responsive element was mapped to a 14 bp sequence located in the proximal promoter region by DNase footprinting and electrophoretic mobility shift assays. The perlecan TGF-beta -responsive element bound specifically to TGF-beta -inducible nuclear proteins which contained NF-1 members of transcription factors. Collectively our results indicate that perlecan is up-regulated by TGF-beta via a transcriptionally mediated control of perlecan promoter and that these effects could be important in the modulation of this proteoglycan during angiogenesis, tissue remodeling, and tumor formation.


EXPERIMENTAL PROCEDURES

Materials and Cell Cultures

Radionucleotides [alpha -32P]dCTP, [alpha -32P]ATP and [gamma -32P]ATP (3000-5000 Ci/mmol; 1 Ci = 37 Gbq) and [14C]chloramphenicol (~100 mCi/mmol) were obtained from Amersham Corp. Restriction endonucleases were purchased from Promega (Madison, WI). Human recombinant TNF-alpha was purchased from Boehringer Mannheim. Human recombinant TGF-beta 2 was a generous gift from Dr. David Olsen (Celtrix Laboratories, CA). HeLa, WiDr colon carcinoma, Saos-2 osteosarcoma, HL-60 promyelocytic leukemia, HT1080 fibrosarcoma, and NIH-3T3 fibroblastic cells were obtained from the American Type Culture Collection. Mouse M2 melanoma cells were obtained from Dr. I. J. Fidler (Houston, TX). Human diploid fibroblast cultures, established from neonatal foreskins, were utilized at passages 3-8. The cell cultures were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Life Technologies, Inc.), 2 mM glutamine, and 100 units/ml penicillin.

Plasmid Construction

Deletion constructs cloned upstream of the CAT reporter gene within the pUC or pBluescript (pBS) vector (Stratagene) were generated as described before (28). The 2.5-kb 5'-flanking region linked to exon 1 (86 bp) was subcloned into the pBS vector and then subcloned into the respective sites in the pUC-CAT vector. Shorter constructs were generated by deletion of the 2.5 kb construct using various restriction endonucleases. Constructs -1800 and -2500/-1800 were generated by digestion of the -2500 construct with HindIII and EcoRV, which deleted ~1800 and ~700-bp fragments between -2500 and -1800. The asymmetric distribution of SmaI sites in the -2500 construct allowed the utilization of partial digestion of the construct thereby generating various 5' and internal deletion products. These constructs were subsequently self-ligated and sequenced to confirm the correct orientation.

Transient Cell Transfection and CAT Assays

Transient transfections of cell types were performed by the calcium phosphate procedure essentially as described before (28, 29). Briefly, subconfluent cells in 75-cm2 flasks were trypsinized, washed, and co-transfected in suspension with 20-40 µg of perlecan promoter-CAT constructs and 10 µg of pSV-beta -galactosidase plasmid to provide an internal standard for normalization of the values. The cells were incubated for 48 h, washed with Hanks' balanced salt solution (Ca2+- and Mg2+-free), and incubated in Dulbecco's modified Eagle's medium for an additional 12 h. The cells were then washed again and assayed for beta -galactosidase activity (29). CAT assays were performed as described before (30). The products were resolved on preslotted thin layer chromatography plates in a chloroform/methanol (95:5) mobile phase and subjected to autoradiography. To quantify the acetylated [14C]chloramphenicol, the autoradiograms were subjected to scanning laser densitometry and computer integration. To study the transcriptional regulation by TGF-beta and TNF-alpha , minor variations to the protocols described above were made. Essentially, cells were treated as above except that the cells were placed in Dulbecco's modified Eagle's medium containing 1% fetal calf serum 4-5 h before the addition of growth factors. In experiments without growth factors, the cells were placed in DMEM containing 1% fetal calf serum. After 40 h of additional incubation, the cells were rinsed with phosphate-buffered saline and harvested. Aliquots corresponding to identical beta -galactosidase activity were used for each CAT assay. After autoradiography, the plates were cut and counted (29).

Isolation of RNA, Northern Blotting, and Immunoblotting

Total RNA was isolated using standard procedures (31) and analyzed by Northern blotting as described before (29). Human perlecan cDNA, clone HS1, encompassing domain III (32) was used as a probe, or the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase was used for normalization of the values. Both probes were radiolabeled (~109 cpm/µg of DNA) by random priming (33) using [alpha -32P]dCTP. The [32P]cDNA-mRNA hybrids were visualized by autoradiography, and the steady-state levels of perlecan or glyceraldehyde-3-phosphate dehydrogenase were quantitated by laser scan densitometry and computer integration, using various exposures to guarantee a linear range. For immunoblotting, human skin fibroblasts were grown to confluence, washed and incubated for 48 h in serum-free medium in the presence or absence of either TGF-beta or TNF-alpha . At the end of each incubation, aliquots of media were processed for slot immunoblotting (6). Briefly, scalar dilutions of media were blotted into nitrocellulose strips using a Minifold II (Schleicher and Schüll); the strips were blocked with 0.05% Tween 20, 4% nonfat dry milk and incubated with the monoclonal antibody 7B5 directed against domain III of human perlecan (4). Following several washes, the membranes were incubated with horseradish peroxidase-labeled goat anti-mouse IgG, washed again, and incubated with the chemiluminescence substrate reagent (15). The membranes were exposed to radiographic films for 0.5-1 min and quantified by laser scanning densitometry.

Preparation of Nuclear Extracts and DNase Footprinting

Nuclear extracts from fibroblasts treated with or without TGF-beta (10 ng/ml) for 18-24 h or from HeLa cells were prepared essentially as described before (34). Protein concentration was determined by a colorimetric method (35). At the end of each purification, aliquots were snap-frozen in liquid nitrogen and stored at -80 °C until analyzed. DNase footprinting analysis was performed to map the nuclear protein binding sites in the proximal promoter region. To this end, the -461 promoter CAT construct was labeled by Klenow with [32P]dCTP on the coding strand at the unique RsrII site, located at -118. Briefly, the RsrII-linearized plasmid was isolated by agarose gel electrophoresis, labeled to high specific activity with Klenow enzyme (New England Biolabs Inc.), purified by column chromatography, and heated at 65 °C to inactivate the enzyme. The fragments were purified and subjected to HindIII digestion, and the released 344-bp 32P-labeled fragment was separated from the ~5-kb vector by agarose gel electrophoresis. The HindIII-RsrII fragment was identified by exposing the gels to an x-ray film, electrophoresed for 10 min onto DEAE paper slotted in the gel, and eluted in TAE buffer (40 mM Tris acetate, 1 mM EDTA, pH 7.2) overnight. The labeled DNA fragments (2-4 × 104 cpm) were first incubated for 15 min on ice with 5-10 µg of nuclear extracts in a buffer containing 1 µg of poly(dI-dC), 10 mM Tris, pH 8.0, 4 mM MgCl2, 1 mM CaCl2, 2 mM dithiothreitol, 1 µg of bovine serum albumin, and 0.1 M KCl. The solutions were then subjected to DNase I digestion (100 milliunits), terminated by 3 volumes of a solution containing EDTA (10 mM) and yeast tRNA, precipitated with ethanol, resuspended in a denaturing buffer, and analyzed on a denaturing 6% gel (36). Radioactive DNA molecular mass markers were run in parallel (29).

Electrophoretic Mobility Shift Assays

Double stranded oligonucleotides were radiolabeled with 32P using the T4 polynucleotide kinase, purified by acrylamide gel electrophoresis, and eluted overnight. A series of oligonucleotides (listed in Table I) were tested in competition assays including the TGF-beta responsive element (Tbeta RE), a 14-bp sequence located between -301 and -314, four mutated Tbeta REs, a 14-bp TGF-beta -responsive sequence of the rat alpha 1(I) collagen promoter, and consensus oligodeoxynucleotides for the NF-1 and AP-2 transcription factors. The labeled probes were incubated for 15 min in a buffer containing 100 mM Hepes, pH 7.9, 1 mM EDTA, 0.2 M NaCl, 40 mM MgCl2, 20 mM dithiothreitol, 20 mM spermidine, 1-2 µg of poly(dI-dC), and 4% glycerol (29), with or without molar excess of oligonucleotide competitors. Nuclear extracts (10-20 µg) from control or TGF-beta -treated fibroblasts or HeLa cells were added to the mixtures and incubated for an additional 15 min. The protein-DNA complexes were separated on 6% polyacrylamide gels (20:1; acrylamide to bisacrylamide) in 22 mM Tris borate, 22 mM boric acid, and 0.5 mM EDTA (37). The gels were fixed, dried under vacuum, and exposed to x-ray films. Protein-DNA complexes were removed from the dried gels, and the radioactivity was measured in a scintillation counter.

Table I.

Structural similarity of TGF-beta -responsive elements in various mammalian promoters

Nucleotide sequence of the TGF-beta responsive element (Tbeta RE) in the human perlecan promoter vis á vis Tbeta REs previously shown to be capable of mediating TGF-beta responsiveness in transient cell transfection or DNA binding assays, with the exception of the human growth hormone where no TGF-beta induction was investigated (54) and for the human alpha 2 integrin for which no functional analysis was provided (44). The 5' and 3' homologous sequences are boldface. The binding sites for NF-1 and AP-2 transcription factors are boldface and underlined. Gaps are introduced to facilitate alignment. The Tbeta RE consensus is based also on the mutational analysis of the sequence as investigated by electrophoretic mobility shift assays (cf. Figs. 8, 9, 10).
Gene Position Sequence Reference

Human perlecan  -314 5'-TGGCCCGGCGGCCC..-3' Present study
Rat alpha 1 (I) collagen  -1643 5'-TGCCCACG..GCCAAG-3' 37
Mouse alpha 2 (I) collagen  -308 5'-TCGCCCTT..GCCAAG-3' 52
Human elastin  -138 5'-TCCCCCAG..GCCTCC-3' 53
Human type I plasminogen activator inhibitor  -560 5'-TGGCTGCAT.GCCCT -3' 55
Human growth hormone  -285 5'-TGGCCTGCG.GCCAG.-3' 54
Human alpha 2 integrin  -235 5'-TGGCTAGGGCGCCA..-3' 44
NF-1 consensus 5'-<UNL><B>TGGC</B></UNL>TTGAA.<UNL><B>GCC</B></UNL>AA- 3' 58
AP-2 consensus 5'-C<UNL><B>GCC</B></UNL>CGC..<UNL><B>GGC</B></UNL>CCGT-3' 38
Tbeta RE consensus 5'-TGGCC.N3-5.GCC. -3'


RESULTS AND DISCUSSION

Cloning and Sequence Analysis of the Human Perlecan 5'-Flanking Region

By screening a chromosome 1-specific phage library with a human cDNA probe encompassing the 5' region of the perlecan gene, we isolated about 4.5 kb of the sequence 5' to exon 1. A computer-assisted analysis, using the Signal and Eukprom programs from the GCG and PCGENE packages, revealed that the 5'-flanking region (Fig. 1) lacked canonical TATA or CAAT boxes but contained several features of a promoter including: (a) a relatively high GC content, primarily evident in the proximal region, with 80% GpC, typical of CpG islands, and (b) the presence of numerous cognate cis-acting elements and palindromic inverted repeats. These features are typical of housekeeping and growth factor-encoding genes that characteristically lack TATA or CAAT boxes and contain multiple transcription initiation sites, as in the human HSPG2 gene (27). The majority of the cognate cis-acting elements were clustered in the first 1.5 kb as related to the major transcription initiation site (Fig. 1). The proximal region contained four GC boxes and 15 consensus hexanucleotide binding sites for the zinc finger transcription factor Sp1, 5 of which were located in the first exon. Another striking feature of the perlecan promoter was the presence of numerous AP-2 motifs (38), eight residing in the first 1.5 kb and two in the most distal area. In addition, numerous AP-2 binding sites were scattered throughout the noncoding strand (not shown). These potential binding sites for the AP-2 transcription factor possess the following two important features: (a) their binding and transcriptional activity are inhibited by SV40 T antigen, and (b) they confer phorbol ester 12-O-tetradecanoylphorbol-13-acetate and cAMP inducibility (39). Of note, SV40 large T antigen inhibits transcription of perlecan in renal tubular epithelial cells (40), and perlecan expression is markedly up-regulated by 12-O-tetradecanoylphorbol-13-acetate in colon cancer (41) or K562 leukemia (6) cells. The proximal promoter region also contained three palindromic inverted repeats in close proximity of each other (between -438 and -204) that, by forming secondary structure, could influence the regulation of perlecan gene expression. The perlecan promoter contained several motifs that bind transcription factors involved in hematopoiesis (42) including two PEA3 motifs, primary targets for signal transduction that bind to Ets members of oncogene, one Ets-1 and one PU.1 box that confers transcriptional activation to B lymphocytes (43), and nine GATA-1 motifs that are involved in erythrocyte differentiation (42). In addition, multiple GATA-1 sequences were present in the noncoding strand (not shown). The adjacent binding sites for GATA and Ets transcription factors at -1830 and -1802, respectively, are similar to those described in the human alpha 2 integrin promoter (44) and suggest the possibility of either cooperative interaction or competitive inhibition. The distal promoter region contained a binding site for NF-kB, a factor that has been involved in interleukin-1 stimulation of transcription in a variety of genes (39). Two fully conserved CTF-NF-1 elements at position -2524 and -1947 in a gene that lacks both TATA and CAAT box sequences are very close to those identified in the human alpha 2 integrin (44) and in a variety of genes including the chicken beta  globin, mouse SPARC and a silencer site in the mouse alpha 2(I) collagen gene (45). In these genes, the CTF-NF1 sequences serve as negative regulatory elements which suppress gene transcription in a cell type-specific fashion (45).


Fig. 1. Regulatory elements of the 5'-flanking region of the human perlecan HSPG2 gene. Putative regulatory motifs (boldface and underlined) are labeled above the coding strand. Palindromic inverted repeats are double-underlined and boldface. The numbers on the right refer to the nucleotide position relative to the major transcription start site (open diamond) at the 5' end of exon 1 (shaded sequence). The candidate cis-acting elements (57) include: ubiquitous zinc finger transcription factor (Sp1); a primary target of signal transduction induced by epidermal growth factor, phorbol ester and serum (PEA3); developmentally regulated dimer that binds to a palindromic sequence most abundant in neural crest cells (AP2); GT-IC binding motif of the SV40 promoter, related to AP3 (TEF-2); glucocorticoid receptor, member of the steroid hormone receptor superfamily (GR); ubiquitous factor, binds to cAMP-responsive element and forms homo- or heterodimers with members of the ATF or Jun families (ATF/CREB); related to members of the Ets family and most abundant in B lymphocytes and macrophages (Pu.1); contributes to the regulation of the SV40 promoter (TEF-1); embryonal long terminal repeat binding protein, expressed in adrenal glands and gonads (ELP); ubiquitous homodimer of Jun or heterodimer of Jun/Fos or Jun/ATF family (AP1); inducer of c-myc gene promoter (PuF); involved in the regulation of SV40 promoter, related to TEF-2 (AP3); induced by IL-6, cooperates with NF-IL6 (H-APF-1); ubiquitous factor, inducible by IL-6 and IL-1, member of C/EBP family (NF-IL6); a component of signaling network of B cells and resting T cells, binds to PEA3 motif, acts in combination with AP1 (Ets-1); expressed in erythroid cells, megakaryocytes and mast cells, activates globin gene, plays autoregulatory roles in its own expression (GATA-1); ubiquitous, induced by TGF-beta , interacts with DNA polymerase to enhance DNA replication (NF1); ubiquitous member of rel-related proteins, released after cytokine stimulation of an inactive complex formed with Ikappa Balpha and Ikappa Bbeta (NFkappa B).
[View Larger Version of this Image (76K GIF file)]


The 5'-Flanking Region of the Human Perlecan Gene Exhibits Promoter Activity in Cells with a Diverse Histogenetic Origin

To prove that the sequence upstream to exon 1 can exhibit transcriptional activity, we transfected a full-length promoter-CAT construct harboring a ~2.5-kb sequence and 86 bp of exon 1, into various human cell lines of epithelial or mesenchymal origin and also into two murine cell lines (Fig. 2). When the values were normalized on beta -galactosidase activity, an internal control for changes in transfection efficiency, functional promoter activity was detected in all the cells tested with maximal activity in the WiDr colon carcinoma cells (Fig. 2B). This is consistent with the fact that these tumor cells express high levels of this proteoglycan (20, 23). The activity of the perlecan promoter in such diverse cell types is in harmony with the widespread tissue distribution of perlecan (4). The activity of perlecan promoter in HL-60 promyelocytic leukemia cells (Fig. 2B) corroborates our previous study which has shown that perlecan is expressed in lymphoreticular cells (6) and further emphasizes the importance of the numerous motifs that could bind cognate transcription factors involved in hematopoiesis (see above). Relatively high perlecan promoter activity was also observed in murine cells, e.g. NIH-3T3 fibroblasts and M2 melanoma cells (Fig. 2B, filled bars), indicating that the human perlecan promoter is active in another species. Taken together, these findings validate the widespread distribution of perlecan demonstrated before by immunohistochemical (4, 7, 46) and in situ hybridization (4, 7) analyses and further suggest that the levels of perlecan gene expression may be regulated by tissue-specific factors.


Fig. 2. The 5'-flanking region of the human perlecan gene exhibits functional promoter activity in a variety of human cells and is also active in murine cells. Panel A shows representative autoradiograms of CAT assays from histogenetically diverse cells (as indicated at the top). The cells were transiently transfected with the 2.5-kb perlecan promoter linked to the CAT gene. Equal amounts of cellular protein, normalized on beta -galactosidase activity, were analyzed for CAT activity on preslotted thin layer chromatography plates in a chloroform/methanol (95:5) mobile phase and subjected to autoradiography. The migration of mono- and diacetylated [14C]chloramphenicol is indicated by asterisk and double asterisk, respectively. O = origin. Lane 1 derives from cells transfected with the promoterless pCAT vector. Panel B is a summary of the data quantified by scanning laser densitometry and computer integration. The various cell lines are indicated at the bottom. The values represent the mean ± S.D. of triplicate determinations and are expressed as percentage of the highest value (WiDr colon carcinoma cells) arbitrarily set at 100%.
[View Larger Version of this Image (33K GIF file)]


Deletion Analysis of the Perlecan Gene Promoter

To investigate in more detail the functional properties of the perlecan gene promoter, we performed reporter gene analysis using various perlecan promoter-CAT fusion plasmids harboring either 5' stepwise or internal deletions (Fig. 3A). In these experiments we used HeLa cells because of their ease of transfection and because we found that they express perlecan,2 a fact that was confirmed by the activity of the full-length promoter-CAT construct in transient cell transfection assays (Fig. 2). After normalization on beta -galactosidase activity, several perlecan promoter constructs exhibited considerable CAT activity. The relative CAT activity of nine constructs based on data from several (n = 6-14) independent experiments is summarized in Fig. 3B. The largest construct, harboring the 2.5 kb of 5'-flanking region, contained maximal promoter activity set arbitrarily to 100%. Shortening the upstream sequence from -2500 to -1800 bp did not produce significant changes in CAT activity. However, three internal deletion constructs (-2500/-283,-2500/-560, and -2500/-1800) showed a marked reduction of CAT activity. Indeed, when these values were corrected for nonspecific base line activity expressed by the two promoterless control plasmids (pBSCAT and pUCCAT), the internal deletions showed essentially complete loss of activity. Consistent with these data, the -461-bp construct maintained 80-90% promoter activity as compared with that detected in the two longest constructs, respectively. Additional reduction was observed with other constructs (Fig. 3B). Sequence analysis of this proximal region revealed, in addition to the multiple AP-2 sites and three palindromic inverted repeats, a regulatory element located at position -450 that consisted of a 5'-GTGAGCGTG-3' sequence with homology to the consensus sequence of the DE1 element 5'-TGACGGTG-3' of the mouse alpha A-crystallin gene (47). This cis-acting motif resembles the cAMP-responsive element sequence (ATF/CREB), 5'-GTGACGT(A/C)(A/C)-3', and behaves as a functional CREB site (47). Therefore, it is possible that this region in the perlecan promoter may be connected with a cAMP transduction. Present in the most proximal promoter region (-132-bp construct) were four GC boxes and several binding sites for Sp1, a well characterized transcription factor that binds GC boxes and stimulates transcription in promoters that contain these sites (39), including the murine syndecan 1 (48) and thrombospondin 1 (49) genes. These results indicate that the 5'-flanking region of the perlecan gene can act as a functional promoter and contains a complex array of cis-acting elements necessary for driving the expression of the perlecan gene in both epithelial and mesenchymal cells.


Fig. 3. Deletion constructs of the human perlecan gene promoter used for transient cell transfection assays (A) and summary of CAT activity (B). Panel A is a schematic representation of stepwise 5' and internal deletion constructs used to test the functional activity of the perlecan promoter in transient cell transfection assays. The numbers on the left indicate the 5' end of the promoter fragments relative to the major transcription start site (+1). Each construct was fused to the CAT gene at position +86 relative to the major transcription start site in exon 1 (filled rectangles). As the negative control we used the promoterless vectors pUC and pBluescript (pBS) (unfilled ovals) linked to the CAT gene. Internal deletions are indicated by a dotted line. Panel B is a summary of CAT expression assays of perlecan gene promoter of various 5' and internal deletion constructs. Promoter activity is expressed as a percentage relative to maximal CAT activity produced by the full-length perlecan promoter -2500 arbitrarily set at 100% (filled bar). The values represent the mean ± S.D. of 6-14 independent experiments (the numbers within bars) each run in either duplicate or triplicate.
[View Larger Version of this Image (18K GIF file)]


Induction of Perlecan Gene Expression in Human Skin Fibroblasts by TGF-beta but Not by TNF-alpha

In the next series of experiments, we wished to investigate the modulation of perlecan gene expression by TGF-beta and TNF-alpha . We utilized normal human diploid skin fibroblasts because, in contrast to HeLa cells, these cells respond to various cytokines and their proteoglycan makeup has been well investigated (7, 29, 50). To this end, post-confluent skin fibroblasts were preincubated for 5 h with 1% fetal calf serum and then incubated for 24 h in the absence or presence of TGF-beta (5 ng/ml) or TNF-alpha (5 ng/ml), either alone or in combination. Total RNA was then extracted and analyzed for perlecan or glyceraldehyde-3-phosphate dehydrogenase gene expression (Fig. 4). While TGF-beta up-regulated the steady state levels of perlecan mRNA (Fig. 4, A and B, lane 2), TNF-alpha had no significant effects (Fig. 4, A and B, lane 3). Interestingly, TNF-alpha did not block the up-regulation of perlecan gene expression induced by TGF-beta (Fig. 4, A and B, lane 4).


Fig. 4. Effects of TGF-beta and TNF-alpha on perlecan mRNA levels in confluent human fibroblast cultures. Three days after reaching confluence, fibroblast cultures were preincubated for 5 h in medium containing 1% fetal calf serum, prior to the addition of either TGF-beta (5 ng/ml) or TNF-alpha (5 ng/ml), or a combination of both cytokines, as indicated at the bottom. After 24 h of incubation, total RNA was extracted and analyzed by Northern hybridization with either perlecan or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA (panel A). Notice up-regulation of perlecan in the presence of TGF-beta (lanes 2 versus lanes 1) in contrast to the lack of any effect by TNF-alpha . Panel B shows the mRNA levels based on the average of four determinations obtained by laser scanning densitometry, with S.D.<15% of the mean.
[View Larger Version of this Image (38K GIF file)]


To verify that the increased perlecan mRNA levels correlated with an increased proteoglycan synthesis, we performed immunoblotting experiments using a monoclonal antibody directed against domain III of perlecan (4). A ~2-fold increase in perlecan protein core biosynthesis in the presence of TGF-beta , but no effect in the presence of TNF-alpha , was observed (Fig. 5). Because most of the synthesized perlecan (>90%) is released as soluble proteoglycan (3), these results indicate that the transcriptional effects of TGF-beta are also seen at the protein level, albeit at a degree lower than that observed at the mRNA level. Our results are in agreement with the stimulation of perlecan biosynthesis and secretion by TGF-beta observed in other cellular systems including colon carcinoma (24), uterine epithelial (25), and 3T3 fibroblastic (26) cells.


Fig. 5. Effects of TGF-beta and TNF-alpha on perlecan protein core biosynthesis. The histogram was generated from the densitometric analysis of immunoslot blottings of scalar dilutions of media conditioned by confluent fibroblasts cultured in the absence or presence of the two cytokines as indicated. The immunoblottings were reacted with a monoclonal antibody directed against perlecan domain III and visualized by chemiluminescence. The values represent the mean ± S.E. (n = 8).
[View Larger Version of this Image (41K GIF file)]


Identification of a TGF-beta -responsive Region in the Perlecan Promoter

The results presented above suggested that the promoter of the perlecan gene harbored sequences that could respond to TGF-beta . To characterize these putative TGF-beta -responsive element(s), we initially tested the largest construct of 2.5 kb for sensitivity to the cytokine. In this series of experiments, the cells were transfected with the promoter CAT-containing plasmid and subjected to subsequent culture in the presence or absence of the cytokine. The results (Fig. 6) showed that the entire promoter of human perlecan was transcriptionally activated by about 2.6-fold upon treatment with TGF-beta . To delineate more accurately the TGF-beta -responsive region, we made additional promoter-CAT constructs and subjected them to the same transient cell transfection assays in which the cells were cultured in the presence or absence of the cytokine. The results showed that the -461-bp construct was markedly stimulated by TGF-beta at a level even higher than the largest (-2500-bp) construct, whereas all additional 5' deletions, including -285-, -189-, -158-, and -132-bp constructs, lacked TGF-beta responsiveness (Fig. 6). Taken together, these results indicate that the proximal 461 bp of the human perlecan promoter contains nearly all the regulatory elements to provide full functional promoter activity and further show that a region of about 177 bp, located between -461 and -285 bp, harbors the TGF-beta responsive sequence(s).


Fig. 6. Transcriptional activation of the perlecan gene promoter by TGF-beta . The values represent the relative promoter activity, based on the conversion of [14C]chloramphenicol driven by perlecan promoter-CAT constructs of various lengths as indicated. The cell extracts were assayed for CAT activity by thin layer chromatography using [14C]chloramphenicol as a substrate after normalization on beta -galactosidase activity from equal amounts of cell lysates cultured for 48 h in the presence or absence of TGF-beta (10 ng/ml). Following autoradiography, the acetylated [14C]chloramphenicol was quantified by scintillation counting of the radioactive areas from the thin layer chromatographic plates. Values are the mean ± S.E. of three independent experiments run in duplicate.
[View Larger Version of this Image (34K GIF file)]


DNase Footprinting and Electrophoresis Mobility Shift Assay of the Proximal Promoter Region

The clear geographic demarcation of TGF-beta action on the perlecan promoter indicated that the major TGF-beta activating element was located between -461 and -285 bp. DNase I footprinting was used to discover cis-acting elements in this relatively short sequence. The results showed at least five distinct footprints, designated a-e (Fig. 7). Interestingly, similar results were obtained with nuclear proteins isolated from either diploid fibroblasts (Fig. 7A, lane 3) or HeLa cells (Fig. 7A, lane 4). However, only footprinting a was located in the region which was responsive to TGF-beta (Fig. 7B, shaded sequence). Footprints b and e harbored Sp1 binding sites, footprint d overlapped with an AP-2 consensus sequence, whereas footprint c was adjacent to an Sp1 binding motif.


Fig. 7. DNase footprinting analysis of the human perlecan proximal promoter region. A, a HindIII-RsrII restriction fragment containing promoter sequences from -118 to -461 was end-labeled at the RsrII site on the coding strand with 32P using the Klenow polymerase. Footprinting was performed by incubating the purified labeled template with 100 milliunits of DNase I either in the absence (lane 1) or the presence of 10 µg of nuclear extracts from fibroblasts (lane 3) or HeLa cells (lane 4). Lane 2 is the probe alone whereas lane 5 contains radioactive DNA size markers. The footprints a-e are labeled by the vertical double arrows. B, nucleotide sequence of the corresponding promoter region extending from -118 to -relative to the major transcription initiation site. The footprintings are boldface and underlined. The region responsive to TGF-beta is shaded.
[View Larger Version of this Image (43K GIF file)]


A closer inspection of the 17-bp sequence footprinted by nuclear proteins from either fibroblasts or HeLa cells, e.g. footprint a in Fig. 7, showed that this sequence harbored a 14-bp motif that was very similar to a TGF-beta -responsive element (Tbeta RE) previously observed in the promoter of rat alpha 1(I) collagen (37, 51), mouse alpha 2(I) collagen (52), human elastin (53), human growth hormone (54), human alpha 2 integrin (44), and human plasminogen activator inhibitor (55) genes (Table I). All of these sequences, with the exception of the human alpha 2 integrin, have been shown to be responsive to TGF-beta by transient cell transfection, DNase footprinting, or electrophoretic mobility shift assay analyses. Structurally, all of these Tbeta REs are characterized by internal NF-1 and AP-2 motifs, which may mediate the action of TGF-beta .

To examine the binding of the perlecan Tbeta RE to nuclear protein, a double-stranded oligomer encompassing the perlecan Tbeta RE was end-labeled and incubated with equal amounts of nuclear proteins extracted from either untreated or TGF-beta -stimulated (5 ng/ml for 24 h) fibroblast nuclei. Electrophoretic mobility shift assay analysis showed that the TGF-beta -stimulated nuclear extracts contained >3 fold more protein binding activity than unstimulated samples and that the binding was specific because it could be displaced by 10-fold molar excess of unlabeled Tbeta RE competitor (Fig. 8A). The results further showed that a comparable response was also obtained with nuclear extracts from cells exposed to TGF-beta for either 12 or 18 h (Fig. 8B).


Fig. 8. Electrophoretic mobility shift assay with perlecan Tbeta RE demonstrates specific binding of nuclear proteins and an increase in binding following treatment with TGF-beta . A, nuclear proteins from human diploid skin fibroblasts (~108 cells) that were incubated with or without TGF-beta (5 ng/ml) for 24 h. The 32P-labeled perlecan Tbeta RE oligomer (see Table I) was incubated (~3 × 105 cpm/pmol DNA) with binding buffer in the presence or absence of 10-fold molar excess of perlecan Tbeta RE cold competitor. After a 15-min incubation, the mixture was incubated with 10 µg of nuclear proteins as indicated on the top. B, in these experiments, 20 µg of nuclear proteins from cells treated with TGF-beta (10 ng/ml) for 12 or 18 h were tested for their ability to bind the 32P-labeled perlecan Tbeta RE oligomer as indicated on the top. The concentration of the Tbeta RE cold competitor was 10-fold (lane 5) and 20-fold (lane 6) molar excess, respectively. Incubation mixtures were separated on 6% polyacrylamide gels in low ionic-strength buffer (51). The migration of the DNA/protein complex is indicated by an asterisk on the left margin.
[View Larger Version of this Image (46K GIF file)]


An NF-1 Binding Site Mediates the TGF-beta -induced Stimulation of Perlecan Transcriptional Activity

To investigate the specificity of perlecan Tbeta RE, competition studies were performed with the collagen alpha 1(I) sequence, or consensus sequence encoding AP-2 and NF-1 binding sites (summarized in Table I). The results showed that equimolar amounts of unlabeled collagen alpha 1(I) Tbeta RE (Fig. 9A, lane 5) or NF-1 (Fig. 9A, lane 7) were as effective as perlecan Tbeta RE (Fig. 9A, lane 4) in disrupting the protein-DNA complex. In contrast, an oligonucleotide harboring the AP-2 consensus sequence was ineffective (Fig. 9A, lane 6). To investigate further the relationship between the perlecan and the collagen alpha 1(I) Tbeta REs, we end-labeled the latter and performed competition studies. The results showed that, under identical electrophoretic conditions and nuclear extract concentrations, the collagen alpha 1(I) Tbeta RE produced a more retarded complex (Fig. 9B, lane 2) and showed induction by TGF-beta (Fig. 9B, lane 3). Interestingly, while unlabeled collagen alpha 1(I) Tbeta RE completely disrupted the DNA-protein complex (Fig. 9B, lane 5) equimolar concentrations of perlecan Tbeta RE reduced the complex by ~60% (Fig. 9B, lane 4) and AP-2 was even less effective (Fig. 9B, lane 6). When the NF-1 consensus sequence was end-labeled and tested with the same nuclear extracts, a DNA-protein complex with a mobility identical to that detected with perlecan Tbeta RE was observed (Fig. 9C, lanes 1 and 2, respectively), further suggesting an affinity of the perlecan Tbeta RE for NF-1 member(s) of transcription factors. In contrast, when recombinant AP-2 protein (Promega) was tested in the same electrophoretic mobility shift assay system, no appreciable displacement of the specific DNA-protein complex was observed (Fig. 9C, lane 5), further corroborating the results obtained with competing AP-2 oligonucleotide. Collectively, these studies support the conclusion that the perlecan Tbeta RE binds to transcription proteins of the NF-1 family, and that the collagen alpha 1(I) Tbeta RE may contain additional transcription factors that differ from those binding to the perlecan Tbeta RE.


Fig. 9. Electrophoretic mobility shift assay with perlecan Tbeta RE (A), collagen alpha 1(I)Tbeta RE (B), or NF-1 (C). A, a 32P-labeled perlecan Tbeta RE oligomer (~3 × 105 cpm/pmol of DNA) was incubated with or without 10-fold molar excess of cold competitors including the perlecan Tbeta RE, collagen alpha 1(I) (Coll-I) Tbeta RE (37), and oligonucleotides containing the consensus binding sequences for either AP-2 (38) or NF-1 (58) transcription factors (see Table I). Following a 15-min incubation, the mixtures were incubated for an additional 15 min with nuclear extracts from fibroblasts which were treated with or without TGF-beta (5 ng/ml) for 24 h, as indicated on the top. B, a 32P-labeled collagen alpha 1(I) (Coll-I) Tbeta RE oligomer (37) was incubated with or without 10-fold molar excess cold competitors including the perlecan Tbeta RE, Coll-I Tbeta RE, or AP-2 consensus. C, 32P-labeled oligomers encoding either the perlecan Tbeta RE (lane 1) or the NF-1 consensus (lane 2) were incubated with cold competitors (lanes 3 and 4, respectively). In lane 5, the labeled perlecan Tbeta RE was incubated with 2 footprinting unit of recombinant AP-2 protein (1 footprinting unit = the amount of protein required to give full protection against DNase I on the SV40 early promoter) before electrophoresis. The migration of the DNA-protein complex is indicated by an asterisk on the left margin. Electrophoretic conditions are the same as those detailed in the legend to Fig. 8.
[View Larger Version of this Image (34K GIF file)]


Finally, to investigate more directly the sequence specificity of the perlecan Tbeta RE, we generated double-stranded oligomers harboring various mutations in the 5' end, 3' end, or central region of the perlecan Tbeta RE (Fig. 10B). Three-bp substitutions in either the 5'- or 3'-GCC region reduced almost completely the ability of the perlecan Tbeta RE to be an effective competitor of the specific DNA-protein complex (Fig. 10A, lanes 5 and 6, respectively). In contrast, 3-bp or 4-bp substitutions in the central domain of the core binding oligomer did not appreciably influence the complex formation (Fig. 10A, lanes 3 and 4, respectively). These results are similar to those obtained with the murine alpha 2(I) collagen promoter where an NF-1-like sequence is responsible for a 5-10-fold transcriptional induction by TGF-beta (52).


Fig. 10. Electrophoretic mobility shift assay with wild-type or mutated species of perlecan Tbeta RE. A, a wild-type 32P-labeled perlecan Tbeta RE oligomer (~3 × 105 cpm/pmol DNA) was incubated with or without 6-fold molar excess cold competitors including the perlecan wild-type Tbeta RE or four Tbeta RE mutants, designated Tbeta REm1 through Tbeta REm4, as illustrated in B. The substituted bp are boldface and underlined. The migration of the DNA-protein complex is indicated by an asterisk on the left margin. Electrophoretic conditions are the same as those detailed in the legend to Fig. 8.
[View Larger Version of this Image (41K GIF file)]


NF-1 was initially identified as a cellular factor that stimulates in vitro replication of adenovirus DNA (56), but it was subsequently shown that this family of transcription factors plays a role in both DNA replication and RNA transcription (57). Indeed, the CAAT-binding/NF-1 family comprises at least six distinct nuclear proteins that are composed of heterologous subunits with binding affinity for imperfect palindromes of TGGC sequences separated by 6 or 7 bases, although they can also bind to a single TGGC sequence (57, 58). Flanking sequences, length and composition of the spacer regions can greatly influence their binding affinity (57). Taking into account the homology and the mutational analysis, thus, a consensus for Tbeta RE (5'-TGGCC . N3-5...GCC-3') could be generated (Table I).

Conclusions

We have cloned and sequenced 2.5-kb of 5'-flanking region of the human perlecan HSPG2 gene and determined for the first time functional promoter activity using transient cell transfection assays. The 5'-flanking region possesses strong basal and inducible promoter activity and is thus assumed to represent the promoter as it operates in vivo. The ubiquitous distribution of perlecan correlates well with functional promoter activity detected in cells with disparate histogenetic origin and also of different species. This study has also identified a Tbeta RE in the proximal promoter region with affinity for members of the NF-1 family of transcription factors. Our data indicate that this sequence is primarily responsible for the transcriptional activation of the perlecan gene by TGF-beta . The results show a complex array of regulatory factors for this proteoglycan and further indicate that the level of constitutive expression in both epithelial and mesenchymal cells is likely guided by the proximal promoter region. The structural and functional characterization of the perlecan gene promoter will now allow dissection of the complex regulation of this molecule during normal development, tissue repair, and tumor growth.


FOOTNOTES

*   This work was supported by National Institutes of Health Grants RO1 CA39481 and RO1 CA47282 (to R. V. I.), PO1 AR38923 (to J. U.), and a grant by the Dermatology Foundation (to A. M.). The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) L81166[GenBank].


   To whom correspondence and reprint requests should be addressed: Dept. of Pathology, Anatomy, and Cell Biology, Rm. 249, Jefferson Alumni Hall, Thomas Jefferson University, 1020 Locust St., Philadelphia, PA 19107. Tel.: 215-503-2208; Fax: 215-923-7969; E-mail: Iozzo{at}lac.jci.tju.edu.
2    R. V. Iozzo, B. Sharma, A. D. Murdoch, and K. G. Danielson, unpublished observations.
1    The abbreviations used are: TGF-beta , transforming growth factor-beta ; TNF-alpha , tumor necrosis factor-alpha ; CAT, chloramphenicol acetyl transferase; Tbeta RE, TGF-beta -responsive element; kb, kilobase pair(s); bp, base pair(s); ATF, activating transcription factor; NF, nuclear factor; CTF, ciliary transcription factor.

Acknowledgments

We thank I. Eichstetter for excellent technical assistance and D. Olsen for providing human recombinant TGF-beta .


REFERENCES

  1. Noonan, D. M., Fulle, A., Valente, P., Cai, S., Horigan, E., Sasaki, M., Yamada, Y., and Hassell, J. R. (1991) J. Biol. Chem. 266, 22939-22947 [Abstract/Free Full Text]
  2. Timpl, R. (1993) Experientia (Basel) 49, 417-428 [Medline] [Order article via Infotrieve]
  3. Iozzo, R. V., Cohen, I. R., Grässel, S., and Murdoch, A. D. (1994) Biochem. J. 302, 625-639 [Medline] [Order article via Infotrieve]
  4. Murdoch, A. D., Liu, B., Schwarting, R., Tuan, R. S., and Iozzo, R. V. (1994) J. Histochem. Cytochem. 42, 239-249 [Abstract/Free Full Text]
  5. SundarRaj, N., Fite, D., Ledbetter, S., Chakravarti, L., and Hassell, J. R. (1995) J. Cell Sci. 108, 2601-2604
  6. Grässel, S., Cohen, I. R., Murdoch, A. D., Eichstetter, I., and Iozzo, R. V. (1995) Mol. Cell. Biochem. 145, 61-68 [Medline] [Order article via Infotrieve]
  7. Murdoch, A. D., Dodge, G. R., Cohen, I., Tuan, R. S., and Iozzo, R. V. (1992) J. Biol. Chem. 267, 8544-8557 [Abstract/Free Full Text]
  8. Iozzo, R. V., and Murdoch, A. D. (1996) FASEB J. 10, 598-614 [Abstract/Free Full Text]
  9. Roberts, R., Gallagher, J., Spooncer, E., Allen, T. D., Bloomfield, F., and Dexter, T. M. (1988) Nature 332, 376-378 [CrossRef][Medline] [Order article via Infotrieve]
  10. Aviezer, D., Hecht, D., Safran, M., Eisinger, M., David, G., and Yayon, A. (1994) Cell 79, 1005-1013 [Medline] [Order article via Infotrieve]
  11. Battaglia, C., Mayer, U., Aumailley, M., and Timpl, R. (1992) Eur. J. Biochem. 208, 359-366 [Abstract]
  12. Battaglia, C., Aumailley, M., Mann, K., Mayer, U., and Timpl, R. (1993) Eur. J. Cell Biol. 61, 92-99 [Medline] [Order article via Infotrieve]
  13. Hayashi, K., Madri, J. A., and Yurchenco, P. D. (1992) J. Cell Biol. 119, 945-959 [Abstract]
  14. Whitelock, J. M., Murdoch, A. D., Iozzo, R. V., and Underwood, P. A. (1996) J. Biol. Chem. 271, 10079-10086 [Abstract/Free Full Text]
  15. Cohen, I. R., Murdoch, A. D., Naso, M. F., Marchetti, D., Berd, D., and Iozzo, R. V. (1994) Cancer Res. 54, 5771-5774 [Abstract]
  16. Isemura, M., Sato, N., Yamaguchi, Y., Aikawa, J., Munakata, H., Hayashi, N., Yosizawa, Z., Nakamura, T., Kubota, A., Arakawa, M., and Hsu, C.-C. (1987) J. Biol. Chem. 262, 8926-8933 [Abstract/Free Full Text]
  17. Lortat-Jacob, H., Kleinman, H. K., and Grimaud, J.-A. (1991) J. Clin. Invest. 87, 878-883 [Medline] [Order article via Infotrieve]
  18. Austria, M. R., and Couchman, J. R. (1993) Mol. Biol. Cell 4, 184a
  19. Klein, G., Conzelmann, S., Beck, S., Timpl, R., and Müller, C. A. (1995) Matrix Biol. 14, 457-465 [CrossRef][Medline] [Order article via Infotrieve]
  20. Iozzo, R. V. (1984) J. Cell Biol. 99, 403-417 [Abstract]
  21. Danielson, K. G., Martinez-Hernandez, A., Hassell, J. R., and Iozzo, R. V. (1992) Matrix 11, 22-35
  22. Iozzo, R. V., Kovalszky, I., Hacobian, N., Schick, P. K., Ellingson, J. S., and Dodge, G. R. (1990) J. Biol. Chem. 265, 19980-19989 [Abstract/Free Full Text]
  23. Iozzo, R. V., and Hassell, J. R. (1989) Arch. Biochem. Biophys. 269, 239-249 [Medline] [Order article via Infotrieve]
  24. Dodge, G. R., Kovalszky, I., Hassell, J. R., and Iozzo, R. V. (1990) J. Biol. Chem. 265, 18023-18029 [Abstract/Free Full Text]
  25. Morris, J. E., Gaza, G., and Potter, S. W. (1994) Cell. Dev. Biol. 30A, 120-128
  26. Nugent, M. A., and Edelman, E. R. (1992) J. Biol. Chem. 267, 21256-21264 [Abstract/Free Full Text]
  27. Cohen, I. R., Grässel, S., Murdoch, A. D., and Iozzo, R. V. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10404-10408 [Abstract]
  28. Wegrowski, Y., Pillarisetti, J., Danielson, K. G., Suzuki, S., and Iozzo, R. V. (1995) Genomics 30, 8-17 [CrossRef][Medline] [Order article via Infotrieve]
  29. Mauviel, A., Santra, M., Chen, Y. Q., Uitto, J., and Iozzo, R. V. (1995) J. Biol. Chem. 270, 11692-11700 [Abstract/Free Full Text]
  30. Naso, M. F., Zimmermann, D. R., and Iozzo, R. V. (1994) J. Biol. Chem. 269, 32999-33008 [Abstract/Free Full Text]
  31. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159 [CrossRef][Medline] [Order article via Infotrieve]
  32. Dodge, G. R., Kovalszky, I., Chu, M.-L., Hassell, J. R., McBride, O. W., Yi, H. F., and Iozzo, R. V. (1991) Genomics 10, 673-680 [Medline] [Order article via Infotrieve]
  33. Feinberg, A. P., and Vogelstein, B. (1984) Anal. Biochem. 137, 266-267 [Medline] [Order article via Infotrieve]
  34. Dignam, J. D., Martin, P. L., Shastry, B. S., and Roeder, R. G. (1983) Methods Enzymol. 101, 582-599 [Medline] [Order article via Infotrieve]
  35. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  36. Santra, M., Danielson, K. G., and Iozzo, R. V. (1994) J. Biol. Chem. 269, 579-587 [Abstract/Free Full Text]
  37. Ritzenthaler, J. D., Goldstein, R. H., Fine, A., and Smith, B. D. (1993) J. Biol. Chem. 268, 13625-13631 [Abstract/Free Full Text]
  38. Williams, T., and Tjian, R. (1991) Genes Dev. 5, 670-682 [Abstract]
  39. Mitchell, P. J., and Tjian, R. (1989) Science 245, 371-378 [Medline] [Order article via Infotrieve]
  40. Piédagnel, R., Prié, D., Cassingéna, R., Ronco, P. M., and Lelongt, B. (1994) J. Biol. Chem. 269, 17469-17476 [Abstract/Free Full Text]
  41. McBain, J. A., Pettit, G. R., and Mueller, G. C. (1990) Cell Growth & Differ. 1, 281-291 [Abstract]
  42. Orkin, S. H. (1995) J. Biol. Chem. 270, 4955-4958 [Free Full Text]
  43. Klemsz, M. J., McKercher, S. R., Celada, A., Van Beveren, C., and Maki, R. A. (1990) Cell 61, 113-124 [Medline] [Order article via Infotrieve]
  44. Zutter, M. M., Santoro, S. A., Painter, A. S., Tsung, Y. L., and Gafford, A. (1994) J. Biol. Chem. 269, 463-469 [Abstract/Free Full Text]
  45. Roy, R. J., Gosselin, P., Anzivino, M. J., Moore, D. D., and Guérin, S. L. (1992) Nucleic Acids Res. 20, 401-408 [Abstract]
  46. Couchman, J. R., Ljubimov, A. V., Sthanam, M., Horchar, T., and Hassell, J. R. (1995) J. Histochem. Cytochem. 43, 955-963 [Abstract/Free Full Text]
  47. Cvekl, A., Kashanchi, F., Sax, C. M., Brady, J. N., and Piatigorsky, J. (1995) Mol. Cell Biol. 15, 653-660 [Abstract]
  48. Vihinen, T., Määttä, A., Jaakkola, P., Auvinen, P., and Jalkanen, M. (1996) J. Biol. Chem. 271, 12532-12541 [Abstract/Free Full Text]
  49. Shingu, T., and Bornstein, P. (1994) J. Biol. Chem. 269, 32551-32557 [Abstract/Free Full Text]
  50. Kähäri, V.-M., Larjava, H., and Uitto, J. (1991) J. Biol. Chem. 266, 10608-10615 [Abstract/Free Full Text]
  51. Ritzenthaler, J. D., Goldstein, R. H., Fine, A., Lichtler, A., Rowe, D. W., and Smith, B. D. (1991) Biochem. J. 280, 157-162 [Medline] [Order article via Infotrieve]
  52. Rossi, P., Karsenty, G., Roberts, A. B., Roche, N. S., Sporn, M. B., and de Crombrugghe, B. (1988) Cell 52, 405-414 [Medline] [Order article via Infotrieve]
  53. Marigo, V., Volpin, D., Vitale, G., and Bressan, G. M. (1994) Biochem. Biophys. Res. Commun. 199, 1049-1056 [CrossRef][Medline] [Order article via Infotrieve]
  54. Courtois, S. J., Lafontaine, D. A., Lemaigre, F. P., Durviaux, S. M., and Rousseau, G. G. (1990) Nucleic Acids Res. 18, 57-64 [Abstract]
  55. Riccio, A., Pedone, P. V., Lund, L. R., Olesen, T., Olsen, H. S., and Andreasen, P. A. (1992) Mol. Cell. Biol. 12, 1846-1855 [Abstract]
  56. Nagata, K., Guggenheimer, R. A., and Hurwitz, J. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 4266-4270 [Abstract]
  57. Faisst, S., and Meyer, S. (1992) Nucleic Acids Res. 20, 3-26 [Medline] [Order article via Infotrieve]
  58. Chodosh, L. A., Baldwin, A. S., Carthew, R. W., and Sharp, P. A. (1988) Cell 53, 11-24 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.